Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features

Caldéraro, Julien; Rousseau, Benoı̂t; Amaddeo, Giuliana; Mercey, Marion; Charpy, Cécile; Costentin, Charlotte; Luciani, Alain; Zafrani, Elie‐Serge; Laurent, Alexis; Azoulay, Daniel; Lafdil, Fouad; Pawlotsky, Jean–Michel

doi:10.1002/hep.28710

Public

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features

Published in Hepatology • Jun 30, 2016

Authors:

Julien Caldéraro

Benoı̂t Rousseau

Giuliana Amaddeo

Abstract

The prognosis of hepatocellular carcinoma (HCC) remains poor, with only one third of patients eligible for curative treatments and very limited survival benefits with the use of sorafenib, the current standard of care for advanced disease. Recently, agents targeting the programmed death ligand 1 (PD...

Subject

Hepatocellular carcinoma

Cytokeratin

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!